First Trust Exchange Traded Fund (FBT) Amex Biotechnology Index

Sell:$206.05Buy:$214.09Price increased$4.51 (2.17%)

Prices delayed by at least 15 minutes
Sell:$206.05
Buy:$214.09
Change:Price increased$4.51 (2.17%)
Deal now
Prices delayed by at least 15 minutes
Sell:$206.05
Buy:$214.09
Change:Price increased$4.51 (2.17%)
Prices delayed by at least 15 minutes
Deal now

ETF Information

Objective

The First Trust NYSE Arca Biotechnology UCITS ETF aims to provide investors with investment results that correspond generally to the price and yield of the NYSE Arca Biotechnology IndexSM, before fees and expenses. The modified equally-weighted index is design to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

  • Leverage -
  • Currency hedgingNo

Costs

  • Ongoing Charge (OCF/TER)0.60%
  • Management fee0.60%
  • Indicative spread3.90%

Replication

  • Replication methodStocks - Full Replication
  • Rebalancing frequencyQuarterly
  • Number of holdings30
  • How is collateral used?Physical replication

Securities lending

  • Is stock lending permitted?No
  • Is stock currently being lent?No
  • Maximum that can be lent -
  • 12 month average % on loan -
  • 12 month return from stock lending -
  • Gross revenue returned -

Counterparties

  • IssuerFirst Trust Global Funds PLC
  • Investment Manager -
  • TrusteeBank of New York Mellon Trust & Depositary Co. Ltd
  • CustodianBank of New York Mellon Trust & Depositary Co. Ltd

Value Assessment

  • Value Assessment review date -
  • Value Assessment next review date -
  • Is Assessment of Value required under COLL? -
  • Outcome of COLL Assessment of Value -
  • Outcome of PRIN Value Assessment or review -
  • Other review related to value and or charges -
  • Further information-

Key facts

  • Issuer
    First Trust Global Funds PLC
  • Structure
    ETF
  • Number of holdings
    30
  • Size
    $13.25m
  • Launch date
    27 May 2020
  • Launch price
    $20.00
  • UCITS
    No
  • Reporting status
    Yes
  • Domicile
    Ireland
  • ISIN
    US33733E2037

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Data provided by Broadridge. Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties. Securities lending data correct as at 02 March 2018. Charge data correct as at date not available. Holdings correct as at 30 September 2024. News service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see Digital Look Ltd Copyright Notice - Sharecast.com for our terms and conditions.